IHC results revealed PD-L1 expression in both newly-diagnosed (GII to GIV) and recurrent gliomas (GIV) in comparison with the tumor margins, which were shown to be PD-L1 negative (Figure 5E). This evidence concerns the gene CD274 and glioma.